Phase II Study of Pre-operative Radiotherapy with Capecitabine and Oxaliplatin for Rectal Cancer and Carcinoembryonic Antigen as a Predictor of Pathological Tumour Response  

Oleh:

Lin, JZ ; Zeng, ZF ; Wu, XJ ; Wan, DS

Jenis: Article from Journal - ilmiah internasional
Dalam koleksi: The Journal of International Medical Research vol. 38 no. 02 (Mar. 2010), page 645-654.
Topik: rectal cancer; capecitabine; oxaliplatin; carcinoembryonic antigen; chemoradiotherapy

Ketersediaan

Perpustakaan FK Nomor Panggil: J11.K.2010.01 Non-tandon: 1 (dapat dipinjam: 0) Tandon: tidak ada

Lihat Detail Induk

Isi artikel

This study investigated the efficacy and tolerability of pre-operative radiotherapy with concurrent capecitabine and oxaliplatin in patients with rectal cancer. Forty-seven patients with rectal adenocarcinoma (stages T3 – T4; node-positive) were enrolled and received radiotherapy (46 Gy in 23 fractions) in combination with capecitabine (1000 mg/m2 twice daily on days 1 – 14 and 22 – 35) and oxaliplatin (130 mg/m2 on days 1 and 22) (XELOX regimen). The main endpoints were safety and efficacy, as assessed by pathological complete response (pCR). All patients received pre-operative chemoradiotherapy (CRT) as planned. The most common severe toxicity was diarrhoea (12.8%); post-operative complications were rare (9.8%). The pCR rate was 20.9% in all patients and 34.8% in patients with normal pre-CRT serum carcinoembryonic antigen (CEA 5 ng/ml or less) level, compared with 5.0% in the patients with elevated CEA (more than 5 ng/ml). In conclusion, pre-operative radiotherapy with concurrent XELOX regimen in rectal cancer patients is feasible and effective. Serum CEA may be a suitable predictor of pCR.

Opini Anda

Klik untuk menuliskan opini Anda tentang koleksi ini!

Kembali